Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive ...
Since the U.S. ousted Venezuela’s president, Nicolás Maduro, earlier this year, officials in Caracas have been looking for ...
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
AI data curation will hit $253B by 2030. As "dirty data" costs firms $12.9M , shifting to agentic memory and synthetic ...
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...
Among adults with chronic rhinosinusitis with nasal polyps, those receiving verekitug vs. placebo at baseline and week 12 had significantly decreased nasal polyp size at week 24, according to a poster ...
A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in ...
A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...
New analysis from TFSF Ventures examines why manual CRM data entry fails businesses and how autonomous AI agents ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results